West Pharmaceutical Services Inc (WST) Investor Brief
A transitional profile supported by a halal-compliant screen and a return profile that looks more rebound-led than fully settled.
West Pharmaceutical Services Inc's growth score of 2.8 out of 4 and maturity score of 2.5 out of 4 still describe a transitional profile rather than a settled one. Product concentration and regulatory exposure leave the case more dependent on execution.
Move through the brief chapter by chapter, from Halal screening and business direction to return interpretation and the final takeaway.
West Pharmaceutical Services Inc (WST) is best understood by focusing on the few questions that matter most to an everyday investor: whether the stock looks Halal, what kind of business it is, and whether returns have justified the risk. West Pharmaceutical Services Inc is currently assessed as halal compliant, and the business profile presently reads as transitional when the growth and maturity signals are considered together.
How to think about stocks
Get occasional insight on how to evaluate stocks, not just what stock to look at next. We write when there is something genuinely useful to add.
By subscribing, you agree to receive this optional email and can withdraw consent later. Read the privacy policy.
At a Glance
West Pharmaceutical Services Inc is currently being reviewed as a healthcare company. Its market capitalization sits around 23.9B USD. The latest EBIT margin is about 19.5%. The indicated dividend yield is roughly 0.3%.
The score mix looks transitional rather than settled, with growth score at about 2.8 out of 4 and maturity score around 2.5 out of 4, which often means the business is still proving what kind of long-term profile it wants to become. Execution quality looks serviceable, but not strong enough to remove the need for ongoing monitoring. The cleaner support currently comes from Interest Coverage and Cashflow Strength, and the resilience score itself sits around 3.2 out of 5.
Is WST Stock Halal?
West Pharmaceutical Services Inc is currently assessed as halal compliant. It operates in a Halal-compliant industry. On the one-year predictive screen, West Pharmaceutical Services Inc is currently viewed as expected to remain compliant within the coming year.
On the financial screen, interest income is around 0.55% versus the AAOIFI threshold of 5.00%, debt is around 2.08% versus the AAOIFI threshold of 30.00%, securities is around 6.83% versus the AAOIFI threshold of 30.00%. These thresholds follow AAOIFI-based screening standards used in purepofo’s methodology. This leaves the financial-ratio picture looking supportive, which is often what investors want to confirm after the business screen is cleared.
| Financial ratio | Current level | Threshold |
|---|---|---|
| Interest Income | 0.55% | 5.00% |
| Debt | 2.08% | 30.00% |
| Securities | 6.83% | 30.00% |
What Does West Pharmaceutical Services Inc Do?
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
The score mix looks transitional rather than settled, with growth score at about 2.8 out of 4 and maturity score around 2.5 out of 4, which often means the business is still proving what kind of long-term profile it wants to become.
The profile holds together mainly because of Reinvestment Capacity, Income Growth, Profit Stability and Cashflow Stability, but Market Expansion and Risk-Adjusted Returns still prevent the story from looking cleaner.
Return Snapshot: WST 1-Year, 3-Year, and 5-Year ROI
Returns are especially accessible for non-specialist investors, which is why the direction of those returns matters as much as their size. The latest 1-year ROI is +33.8%. The trailing 3-year compounded ROI is -13.4%. The longer 5-year compounded ROI is -27.0%.
The shorter horizon is noticeably stronger than the deeper history, which can be a constructive early sign if fundamentals are also improving. On a risk-adjusted basis, the stock has held up well, which improves the quality of the raw return story.
Analyst pricing context suggests a path from around 337.75 USD to 404.73 USD, which equates to roughly +20% with 16 analyst estimates. That should support the discussion, not replace independent judgment.
What Looks Good and Which WST Risks to Watch
The clearest positives are improving recent momentum, reinvestment capacity and income growth.
What could most easily weaken the case from here is product concentration and regulatory exposure.
Bottom Line: Is WST a Good Stock to Buy?
The overall investment impression is that West Pharmaceutical Services Inc remains a selective candidate rather than an automatic high-conviction holding: growth at 2.8 out of 4 and maturity at 2.5 out of 4, which still describes a transitional business profile and needs further operating confirmation.
Use the investor brief as a starting point, then continue into the broader purepofo research workflow when you want deeper methodology, screening, or comparative context.
This article is provided for informational and educational purposes only. It does not constitute investment, legal, tax, Shariah, or other professional advice, and it is not a recommendation or solicitation to buy, sell, or hold any security. The content is general in nature, is not tailored to your personal circumstances or objectives, and should not be relied on as the sole basis for any investment decision.
Halal assessments, ratings, forecasts, and classifications reflect purepofo's methodology at the time of publication. They may change as company fundamentals, market data, methodology inputs, AAOIFI-based screening interpretations, or other information change. Proprietary scores and forward-looking assessments are inherently uncertain and are not guaranteed to be accurate, complete, or timely.
Third-party data may be used. purepofo does not guarantee the accuracy, completeness, or timeliness of third-party information and is not responsible for errors, omissions, or content provided by others. Logos and trademarks remain the property of their respective owners and are used for identification only.
You should carry out your own research and, where appropriate, consult qualified financial, legal, tax, and Shariah advisers before making any decision. Please also review our Terms and Conditions.
powered by innovation.
© 2026 purepofo.
All rights reserved.
Follow us on
